Weave's $8.33 Price Target Points to 27.58% SaaS Upside

For SaaS operators and investors, Weave Communications' head-to-head with Surgical Science Sweden offers a useful read on how the market values vertical healthcare software. Weave combines customer experience, payments, and workflow tools for SMB healthcare practices, and its $8.33 analyst target implies 27.58% upside. The comparison underscores that revenue scale and platform breadth can win investor favor even when a smaller competitor posts higher earnings.

On August 2, 2026, two automated equity reports from TickerReport and DailyPolitical published nearly identical head-to-head surveys of Weave Communications and Surgical Science Sweden AB. Both reports rely on MarketBeat data and reach the same conclusion: Weave Communications wins on six of nine compared factors, carries a stronger consensus rating, and offers a consensus price target of $8.33, implying 27.58 percent upside from the price used in the comparison. The reports, however, are algorithmically generated and do not include original analyst interviews or independently audited financials. Readers should treat the comparison as a data aggregation rather than a deep fundamental research note.

“

Weave combines customer experience, payments, and workflow tools for SMB healthcare practices, and its $8.33 analyst target implies 27.58% upside.

The juxtaposition is unusual because the two companies serve different parts of the healthcare economy. Weave Communications operates a customer experience and payments software platform aimed at small and medium-sized healthcare businesses in the United States and Canada. Its tools help practices manage patient interactions, payments, and administrative workflows. Surgical Science Sweden AB is a Swedish medical technology company focused on virtual reality simulators for surgical training and education. One company sells operational efficiency to outpatient providers; the other sells clinical skill development to hospitals, academic medical centers, and medical device companies. Comparing them purely as healthcare stocks therefore obscures the fact that they are not direct competitors.

Even so, the survey highlights how market participants are currently valuing vertical healthcare software relative to specialized medical training hardware and software. Weave's reported 86.8 percent institutional ownership is the most striking data point. Strong institutional sponsorship often signals that large money managers, endowments, and hedge funds believe a company will outperform over the long term. Insider ownership of 16.4 percent adds another layer, though the two figures may overlap or reflect different reporting dates because they sum to more than 100 percent. The data asymmetry is notable: the reports provide ownership details for Weave but not for Surgical Science Sweden, which may reflect reporting differences or simply the template's focus.

Analyst sentiment further favors Weave. The reports cite a consensus price target of $8.33 and a potential upside of 27.58 percent, with a stronger consensus rating than Surgical Science Sweden. Yet Surgical Science Sweden has lower revenue but higher earnings, suggesting a more profitable business model despite its smaller scale. This is an important nuance for investors: Weave may be growing revenue faster or operating on a larger base, but Surgical Science appears to generate superior earnings relative to its revenue base. Without detailed net margins, return on equity, and return on assets from the underlying tables, the exact spread cannot be verified from the text alone. The articles mention those tables but do not provide the figures in a readable form.